$DVAX
DYNAVAX TECHNOLOGIES CORP

2023 Q4 Form 10-Q Financial Statement

#000095017023058225 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $55.60M $69.51M
YoY Change -69.87% -58.56%
Cost Of Revenue $8.689M $13.20M
YoY Change -88.79% -78.48%
Gross Profit $46.91M $56.30M
YoY Change -56.16% -47.09%
Gross Profit Margin 84.37% 80.99%
Selling, General & Admin $39.79M $38.05M
YoY Change 30.98% 18.76%
% of Gross Profit 84.83% 67.59%
Research & Development $14.12M $14.12M
YoY Change 9.84% 8.9%
% of Gross Profit 30.1% 25.07%
Depreciation & Amortization $1.142M $1.100M
YoY Change 36.44% 23.6%
% of Gross Profit 2.43% 1.95%
Operating Expenses $53.91M $52.17M
YoY Change 24.69% 15.92%
Operating Profit -$7.005M $5.116M
YoY Change -110.99% -91.67%
Interest Expense $7.864M $1.691M
YoY Change 197.88% 0.36%
% of Operating Profit 33.05%
Other Income/Expense, Net $1.623M $266.0K
YoY Change -26.19% -227.88%
Pretax Income $996.0K $14.15M
YoY Change -98.53% -77.93%
Income Tax $777.0K -$100.0K
% Of Pretax Income 78.01% -0.71%
Net Earnings $219.0K $14.29M
YoY Change -99.68% -77.6%
Net Earnings / Revenue 0.39% 20.56%
Basic Earnings Per Share $0.11
Diluted Earnings Per Share $0.00 $0.10
COMMON SHARES
Basic Shares Outstanding 129.3M 128.8M
Diluted Shares Outstanding 154.2M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $742.3M $720.4M
YoY Change 18.88% 22.84%
Cash & Equivalents $150.3M $154.5M
Short-Term Investments $592.0M $565.9M
Other Short-Term Assets $19.00M $19.00M
YoY Change -77.82% -83.15%
Inventory $53.29M $49.41M
Prepaid Expenses
Receivables $40.61M $46.30M
Other Receivables $3.926M $600.0K
Total Short-Term Assets $859.1M $835.7M
YoY Change -6.31% -10.43%
LONG-TERM ASSETS
Property, Plant & Equipment $37.30M $36.18M
YoY Change -0.8% 2.35%
Goodwill $2.067M $1.981M
YoY Change 3.04% 7.96%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $74.33M $74.15M
YoY Change 2144.79% 2122.18%
Total Long-Term Assets $138.0M $137.3M
YoY Change 100.36% 106.75%
TOTAL ASSETS
Total Short-Term Assets $859.1M $835.7M
Total Long-Term Assets $138.0M $137.3M
Total Assets $997.1M $972.9M
YoY Change 1.14% -2.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.245M $3.120M
YoY Change 63.34% 2.3%
Accrued Expenses $49.45M $43.46M
YoY Change 60.97% 13.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.20M $54.26M
YoY Change -58.56% -77.77%
LONG-TERM LIABILITIES
Long-Term Debt $222.7M $222.4M
YoY Change 0.51% 0.5%
Other Long-Term Liabilities $74.00K $321.0K
YoY Change -80.73% 27.89%
Total Long-Term Liabilities $74.00K $321.0K
YoY Change -80.73% 27.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.20M $54.26M
Total Long-Term Liabilities $74.00K $321.0K
Total Liabilities $375.0M $368.0M
YoY Change -7.36% -26.21%
SHAREHOLDERS EQUITY
Retained Earnings -$930.6M -$930.8M
YoY Change 0.69% -6.16%
Common Stock $1.555B $1.542B
YoY Change 2.92% 2.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $622.1M $604.9M
YoY Change
Total Liabilities & Shareholders Equity $997.1M $972.9M
YoY Change 1.14% -2.64%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $219.0K $14.29M
YoY Change -99.68% -77.6%
Depreciation, Depletion And Amortization $1.142M $1.100M
YoY Change 36.44% 23.6%
Cash From Operating Activities $13.76M $31.10M
YoY Change -60.62% -49.48%
INVESTING ACTIVITIES
Capital Expenditures $1.704M $400.0K
YoY Change 7.37% -131.23%
Acquisitions
YoY Change
Other Investing Activities -$18.52M -$105.7M
YoY Change -40.97% -10.25%
Cash From Investing Activities -$20.23M -$106.1M
YoY Change -38.64% -10.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.786M 3.000M
YoY Change 1067.32% -62.77%
NET CHANGE
Cash From Operating Activities 13.76M 31.10M
Cash From Investing Activities -20.23M -106.1M
Cash From Financing Activities 1.786M 3.000M
Net Change In Cash -4.679M -72.00M
YoY Change -319.26% 45.66%
FREE CASH FLOW
Cash From Operating Activities $13.76M $31.10M
Capital Expenditures $1.704M $400.0K
Free Cash Flow $12.06M $30.70M
YoY Change -63.85% -51.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001029142
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34207
dei Entity Registrant Name
EntityRegistrantName
Dynavax Technologies Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0728374
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Powell Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
848-5100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVAX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
129260850
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154511000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
565905000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
422391000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
46347000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
145130000
CY2023Q3 us-gaap Other Receivables
OtherReceivables
519000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
2385000
CY2023Q3 us-gaap Inventory Net
InventoryNet
49412000
CY2022Q4 us-gaap Inventory Net
InventoryNet
59446000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18972000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
85629000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
835666000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
916985000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36183000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37596000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24949000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25745000
CY2023Q3 us-gaap Goodwill
Goodwill
1981000
CY2022Q4 us-gaap Goodwill
Goodwill
2006000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74154000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3518000
CY2023Q3 us-gaap Assets
Assets
972933000
CY2022Q4 us-gaap Assets
Assets
985850000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3120000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3211000
CY2023Q3 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3290000
CY2022Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4775000
CY2023Q3 dvax Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
0
CY2022Q4 dvax Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
107738000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43462000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30719000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4392000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3631000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
54264000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150074000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3085000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3922000
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
222415000
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
221578000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30680000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32801000
CY2023Q3 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2022Q4 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
0
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
321000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
384000
CY2023Q3 us-gaap Liabilities
Liabilities
368017000
CY2022Q4 us-gaap Liabilities
Liabilities
404837000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
129195000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129195000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
127604000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127604000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
129000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
128000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1541549000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1510518000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5959000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5438000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-930803000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-924195000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
604916000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
972933000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
985850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69514000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
167735000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
176688000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
538191000
CY2023Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
13229000
CY2022Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
61334000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
41478000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
184665000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14116000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12962000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40767000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33746000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38053000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32042000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111667000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
100393000
CY2023Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2022Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2023Q3 dvax Bad Debt Expense
BadDebtExpense
0
CY2022Q3 dvax Bad Debt Expense
BadDebtExpense
0
dvax Bad Debt Expense
BadDebtExpense
12313000
dvax Bad Debt Expense
BadDebtExpense
0
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
64398000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
106338000
us-gaap Costs And Expenses
CostsAndExpenses
205225000
us-gaap Costs And Expenses
CostsAndExpenses
317804000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
5116000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
61397000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28537000
us-gaap Operating Income Loss
OperatingIncomeLoss
220387000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
8462000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2562000
us-gaap Investment Income Interest
InvestmentIncomeInterest
22437000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3588000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1691000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1685000
us-gaap Interest Expense
InterestExpense
5065000
us-gaap Interest Expense
InterestExpense
5048000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
1993000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
2026000
us-gaap Sublease Income
SubleaseIncome
5584000
us-gaap Sublease Income
SubleaseIncome
5660000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
266000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-208000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
218000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14146000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
64092000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5363000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
226325000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
283000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1245000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
902000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
14293000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
63809000
us-gaap Net Income Loss
NetIncomeLoss
-6608000
us-gaap Net Income Loss
NetIncomeLoss
225423000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.79
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.1
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.51
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128988000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127062000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128515000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125997000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154196000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151538000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128515000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150433000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
14293000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
63809000
us-gaap Net Income Loss
NetIncomeLoss
-6608000
us-gaap Net Income Loss
NetIncomeLoss
225423000
CY2023Q3 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
426000
CY2022Q3 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-395000
dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-105000
dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-2296000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1013000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2307000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-416000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4700000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-587000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2702000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-521000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6996000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13706000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
61107000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7129000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
218427000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
577205000
CY2023Q3 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
2722000
CY2023Q3 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-162000
CY2023Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
758000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10687000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-587000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
14293000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
604916000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
4339000
dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-6125000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1535000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31283000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-521000
us-gaap Net Income Loss
NetIncomeLoss
-6608000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
604916000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
422799000
CY2022Q3 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
7337000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
720000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8613000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2702000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
63809000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
500576000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
222374000
dvax Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
24670000
dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
9487000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1430000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24188000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6996000
us-gaap Net Income Loss
NetIncomeLoss
225423000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
500576000
us-gaap Net Income Loss
NetIncomeLoss
-6608000
us-gaap Net Income Loss
NetIncomeLoss
225423000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3228000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2975000
dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
2090000
dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
2244000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11313000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1969000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
us-gaap Share Based Compensation
ShareBasedCompensation
31283000
us-gaap Share Based Compensation
ShareBasedCompensation
24188000
dvax Bad Debt Expense
BadDebtExpense
12313000
dvax Bad Debt Expense
BadDebtExpense
0
dvax Non Cash Interest Expense
NonCashInterestExpense
2246000
dvax Non Cash Interest Expense
NonCashInterestExpense
2222000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
14485000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-40935000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-698000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9435000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55759000
dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
0
dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
-146928000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4650000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26240000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-730000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-61000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-612000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
301000
dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
0
dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
-21110000
dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
2635000
dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
2366000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-262469000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
11355000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-19043000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
86797000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27768000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
484040000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
514676000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
351735000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
236200000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2381000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5552000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1000000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-133686000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-283028000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8455000
dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
4339000
dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
9487000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
494498000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
493376000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
72919000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1535000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1430000
dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
6264000
dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-390000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19372000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-155000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1755000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47434000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-237643000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154777000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198765000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1413000
us-gaap Income Taxes Paid
IncomeTaxesPaid
788000
us-gaap Interest Paid Net
InterestPaidNet
2819000
us-gaap Interest Paid Net
InterestPaidNet
2819000
dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
71307000
dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
0
dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
-60337000
dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
0
CY2023Q3 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
-47401000
CY2022Q3 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
704000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
973000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1332000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2475000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that may affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes, including amounts of revenues and expenses during the reported periods. Management’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates, judgments and methodologies. Significant estimates and assumptions in the unaudited condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets; valuation procedures for right-of-use assets and operating lease liabilities; valuation of inventory; research and development expenses; contingencies and share-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
72529000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1377000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4172000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4851000
us-gaap Operating Lease Payments
OperatingLeasePayments
5300000
us-gaap Operating Lease Payments
OperatingLeasePayments
5100000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154511000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198576000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436189000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
266000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
207000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
189000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
219000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154777000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198765000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
567417000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
565905000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
27469000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25517000
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17515000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
23934000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4428000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
9995000
CY2023Q3 us-gaap Inventory Net
InventoryNet
49412000
CY2022Q4 us-gaap Inventory Net
InventoryNet
59446000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2031-03-31
us-gaap Lessee Operating Sublease Option To Extend
LesseeOperatingSubleaseOptionToExtend
The subtenant has no option to extend the sublease term
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
2000000
us-gaap Sublease Income
SubleaseIncome
5600000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
2000000
us-gaap Sublease Income
SubleaseIncome
5700000
CY2023Q3 dvax Percentage Of Excess Rent Paid To Landlord
PercentageOfExcessRentPaidToLandlord
0.50
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1392000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4390000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3631000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30680000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32801000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
35070000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
36432000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Remainder Of Fiscal Year
LessorSubleaseRentalsPaymentsToBeReceivedRemainderOfFiscalYear
1405000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1873000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
5684000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7579000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
5854000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6954000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
6030000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6096000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
6211000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6026000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
21500000
CY2023Q3 dvax Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
21171000
CY2023Q3 dvax Lessor Sublease Rentals Payments To Be Received Due
LessorSubleaseRentalsPaymentsToBeReceivedDue
46684000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
49699000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14629000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
35070000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y9M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
14293000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
63809000
dvax Description Of Avecia Supply Agreement
DescriptionOfAveciaSupplyAgreement
On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). As of September 30, 2023, we have not placed any manufacturing orders under the Avecia Supply Agreement. As of September 30, 2023 and December 31, 2022, we have no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant.
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12300000
CY2023Q2 dvax Prepayment Of Advance Payment
PrepaymentOfAdvancePayment
13500
CY2023Q2 dvax Repayment Of Advance From Customer
RepaymentOfAdvanceFromCustomer
47400000
CY2023Q3 us-gaap Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
33700000
CY2023Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
344800000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4227000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4228000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
282000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
273000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
838000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
812000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1691000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1682000
us-gaap Interest Expense Debt
InterestExpenseDebt
5065000
us-gaap Interest Expense Debt
InterestExpenseDebt
5040000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69514000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
167735000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
176688000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
538191000
us-gaap Contract With Customer Asset Change In Method Credit Loss Expense Reversal
ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal
71307000
CY2023Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss Noncurrent
ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent
71307000
us-gaap Net Income Loss
NetIncomeLoss
-6608000
us-gaap Net Income Loss
NetIncomeLoss
225423000
CY2023Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-291000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14293000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
63809000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6608000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
225132000
CY2023Q3 dvax Addition Of Undistributed Earnings Allocated To Participating Securities
AdditionOfUndistributedEarningsAllocatedToParticipatingSecurities
0
CY2022Q3 dvax Addition Of Undistributed Earnings Allocated To Participating Securities
AdditionOfUndistributedEarningsAllocatedToParticipatingSecurities
0
dvax Addition Of Undistributed Earnings Allocated To Participating Securities
AdditionOfUndistributedEarningsAllocatedToParticipatingSecurities
0
dvax Addition Of Undistributed Earnings Allocated To Participating Securities
AdditionOfUndistributedEarningsAllocatedToParticipatingSecurities
291000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
CY2023Q3 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
1268000
CY2022Q3 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
1262000
us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
0
us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
3780000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
15561000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
65071000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6608000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
227402000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128988000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127062000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128515000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125997000
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3665000
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2933000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2784000
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2022Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
109000
CY2023Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
21543000
CY2022Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
21543000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
21543000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154196000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151538000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128515000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150433000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5605000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5214000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36847000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7417000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129194842
CY2022Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
15000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9339000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.7
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M9D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16291000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1968000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.14
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
556000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.8
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
83000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
260000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
21.42
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10408000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M17D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46599000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10211000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y4M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
45949000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6843000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M20D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
34772000
CY2023Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
700000
us-gaap Restricted Stock Expense
RestrictedStockExpense
1800000
CY2022Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
200000
us-gaap Restricted Stock Expense
RestrictedStockExpense
600000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10687000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
8613000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
31283000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
24188000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1200000
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.01
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.229
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.004

Files In Submission

Name View Source Status
dvax-20230930_htm.xml Edgar Link completed
0000950170-23-058225-index-headers.html Edgar Link pending
0000950170-23-058225-index.html Edgar Link pending
0000950170-23-058225.txt Edgar Link pending
0000950170-23-058225-xbrl.zip Edgar Link pending
dvax-20230930.htm Edgar Link pending
dvax-20230930.xsd Edgar Link pending
dvax-ex10_1.htm Edgar Link pending
dvax-ex31_1.htm Edgar Link pending
dvax-ex31_2.htm Edgar Link pending
dvax-ex32_1.htm Edgar Link pending
dvax-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
dvax-20230930_cal.xml Edgar Link unprocessable
dvax-20230930_def.xml Edgar Link unprocessable
dvax-20230930_lab.xml Edgar Link unprocessable
dvax-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending